Wednesday, November 26th @ 1:30PM (CST)

Pulmonary Fibrosis and Interstitial Lung Disease (ILD) Support Meeting 
Upcoming Therapy for Pulmonary Fibrosis - Nerandomilast

Join us on November 26th at 1:30 pm to hear Dr. Stacey Lok, respirologist and pulmonary fibrosis specialist from Saskatoon, discuss a new therapy for pulmonary fibrosis. Nerandomilast is a medication being studied for pulmonary fibrosis that may slow down the harmful processes where lung tissue becomes stiff (fibrosis) and inflamed by targeting a specific enzyme called PDE4B, which plays a key role in triggering these damaging processes.

We are proud to continue our partnership with the Saskatchewan Health Authority's Live Well Pulmonary Fibrosis Program to host these support meetings.

About Dr. Stacey Lok

Dr. Stacey Lok is an Assistant Professor in the Division of Respirology, Critical Care, and Sleep Medicine at the University of Saskatchewan. She completed her undergraduate medical training, internal medicine and respirology residency at the University of Saskatchewan followed by an Interstitial Lung Disease fellowship at the University of Calgary. She was a recipient of the Canadian Pulmonary Fibrosis Foundation Robert Davidson Fellowship. Her primary clinical and research interest is in interstitial lung disease and she is an investigator for the Canadian Registry for Pulmonary Fibrosis.